Effect ot Fenugreek in treatment of fatty liver

Phase 2

• Conditions: none alcoholic fatty liver disease.; Fatty (change of) liver, not elsewhere classified

• Registration Number: IRCT2013102015083N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

the level of ALT and AST greater than 1.5 and less than 10 times normal level; Ultrasound evidence confirm fatty liver disease; age between 18-70 years old; negative pregnancy test for women in reproductive age (up to two weeks prior to the study); negative for hepatitis B and C; BMI: 18.5 to 40; sign the consent form.
Exclusion criteria: history of more than one unit of alcohol consumption (one value for the Spirits (vodka; whiskey); Wine and Beer are respectively 30-45 cc; 120-150 cc and 360 cc.); fatty liver controller medications; Glucose lowering drugs; Cholesterol lowering drugs; Hypotensive drugs; consumption of vitamin E; taking coenzyme Q10; administration of corticosteroids & glucocorticoids; thyroxin administration; administration of drugs that cause fatty liver; diabetes (type 1 and 2); history of cancer in the past; hepatocellular carcinoma; renal failure (creatinine> 1.5 x ULN); chronic pancreatitis; cirrhosis; uncontrolled hypertension (above 180 mm Hg systolic blood pressure); heart disease; autoimmune hepatitis; primary biliary cirrhosis; primary sclerosing cholangitis (alkaline phosphatase levels greater than 3 times normal); Wilson's disease; alpha-1 antitrypsin deficiency and coronary artery disease; symptoms of hypothyroidism; hyperthyroidism; disorders of the hypothalamic – pituitary; liver transplantation; pregnant or lactating women; and those who cannot use contraceptives.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
iver stiffness. Timepoint: At baseline and 12 weeks after intervention. Method of measurement: Fibro scan.;Insulin resistance. Timepoint: At baseline and 6 and 12 weeks after intervention. Method of measurement: blood sample.